Full-Time

Market Access Consultant

WEP Clinical

WEP Clinical

201-500 employees

Specialist services for early access medicines

No salary listed

Remote in UK

Hybrid

Hybrid work is required in the United Kingdom.

Bachelor's, Master's

Category
Consulting (1)
Required Skills
Lead Generation

Get referred to WEP Clinical

See people who can refer or advise you

Requirements
  • A Bachelor's degree in a scientific discipline and/or a Master of Science in Health Economics.
  • At least 5 years of consulting or relevant business experience in market access, reimbursement, pricing, and/or health economics, or an equivalent combination of education and experience.
  • Proven experience in market access dossier development and pricing analysis.
  • Demonstrated ability to work cross-functionally with internal teams and external stakeholders.
  • Experience developing clear, compelling slides and materials for client presentations.
  • Fluency in English.
  • A strong interest in medical research, healthcare delivery, and the pharmaceutical industry.
Responsibilities
  • Lead key client programs alongside the senior Market Access team, focusing on strategic consulting and ex-US funding access initiatives.
  • Serve as the primary point of contact for client engagements and deliver integrated solutions across pricing, market access, patient access, data collection, product supply, and regulatory support as needed.
  • Collaborate with cross-functional teams to develop solutions supporting Market Access objectives and broader company goals.
  • Build an industry network, identify new business opportunities, and support Business Development efforts through client presentations and tailored proposals.
  • Partner with the Business Development team to train and enable lead generation by articulating integrated Market Access and Funded NPP services.
  • Develop Market Access presentations and present them to prospective and existing clients following lead identification.
  • Assess client requirements, define project scope, and structure Market Access programmes with senior Market Access leadership.
  • Lead research, analysis, reporting, and pricing due diligence to support client needs assessment, programme design, and proposal development.
  • Own client proposal development and provide analysis supporting decision-making and programme approval.
  • Develop and manage detailed workstream project plans covering objectives, deliverables, timelines, budgets, stakeholder alignment, and client engagement plans.
  • Lead client meetings and cross-functional teams, provide project updates, advise on patient access and market access strategy, and manage stakeholder expectations.
  • Manage end-to-end delivery of Market Access programmes in line with statements of work, including communications, reporting, issue resolution, and coordination with external partners.
  • Provide strategic, actionable insights and recommendations supporting clients' development and commercialisation strategies, including Early Access Programmes, asset profiles, competitor landscaping, and price and reimbursement negotiations.
  • Collaborate with WEP teams, including Finance, to ensure programme execution, accurate invoicing, successful project delivery, repeat business, and representation at key congresses.
Desired Qualifications
  • Proficiency in an additional European language.
  • Experience or interest related to medical research, healthcare delivery, and the pharmaceutical industry.

WEP Clinical provides access to unlicensed or scarce medicines through Expanded Access Programs (EAP) and Managed Access Programs (MAP) for hospitals and physicians in over 60 countries. It uses a global sourcing network and handles import authorizations to obtain medicines that aren’t commercially available or are in short supply. A team of country managers and in-house pharmacists with local language skills coordinates and ships medications to healthcare providers. Revenue comes from service fees for managing access programs and sourcing medicines, with the goal of getting necessary treatments to patients quickly.

Company Size

201-500

Company Stage

N/A

Total Funding

N/A

Headquarters

Morrisville, North Carolina

Founded

2008

Get referred to WEP Clinical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • January 2026 Siron Clinical deal expands European footprint and trial delivery capacity.
  • June 2026 WEP still advertised active PA-NPP and case studies for multiple medicines.
  • Chiswick Tower London operations and 2026 access-summit activity signal ongoing commercial momentum.

What critics are saying

  • Expanded-access demand depends on sponsor pipelines; rare-drug stoppages can instantly shrink revenue.
  • Siron integration risks distracting management and diluting execution across Europe in 2026.
  • A major regulatory or supply failure in patient access would damage trust and referrals.

What makes WEP Clinical unique

  • WEP Clinical combines expanded access, named-patient supply, and Phase I-IV CRO services.
  • January 2026 Siron Clinical acquisition deepens European monitoring, QA, and regulatory submissions.
  • Its 60-country network and local pharmacists handle import authorizations for unlicensed medicines.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Disability Insurance

Life Insurance

Parental Leave

Flexible Work Hours

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

28%

1 year growth

28%

2 year growth

28%
WEP Clinical
Jul 1st, 2026
WEP Clinical announces new London office at Chiswick Business Park.

WEP Clinical announces new London office at Chiswick Business Park. WEP Clinical, a global Clinical Research Organization (CRO) supporting biopharmaceutical partners across the full drug development lifecycle, is pleased to announce the opening of its new London office at Chiswick Business Park. The move marks a deliberate step forward for WEP Clinical as the company experiences significant momentum across its phase 1-4 clinical trial management services and reflects a broader commitment to ensuring its people have access to a workspace that matches the quality and ambition of the work they deliver. Chiswick Business Park is one of west London's most respected business destinations, comprising 1.8 million square feet of award-winning office accommodation and a community built around the belief that people do their best work when they enjoy where they work. That philosophy resonates strongly with WEP Clinical's own people-first culture and its focus on collaboration, wellbeing, and shared success. "As WEP Clinical continues to grow, particularly across our clinical trial management offering, it felt like the right moment to ensure our London team has an environment that truly reflects who we are as a company," said Jas Khera, CEO and Founder of WEP Clinical. "Chiswick Park is a genuinely exceptional place to work, and we are excited to bring our team into a space designed for connection, innovation, and the kind of high-quality thinking our partners and their patients depend on." The new office provides modern, flexible workspaces that support cross-functional collaboration and reinforce WEP Clinical's commitment to building a culture where people can thrive. It further strengthens the company's UK presence as WEP continues to expand its global footprint and deepen its partnerships across the biopharmaceutical industry. About WEP Clinical WEP Clinical is a global CRO with expertise in designing, managing, and executing phase 1-4 Clinical Trials, Expanded and Post-Trial Access Programs, and Clinical Trial Home Nursing solutions across multiple therapeutic areas. With a strong focus on proactive project management, scientific integrity, regulatory compliance, and patient-centric execution, WEP supports pharmaceutical and biotech companies in bringing life-changing therapies to market and creating broader treatment access opportunities for patients. Learn more at www.wepclinical.com.

WEP Clinical
Jan 5th, 2026
WEP Clinical Acquires Siron Clinical

WEP Clinical acquires Siron Clinical. WEP Clinical acquires Netherlands-based CRO Siron Clinical, expanding global Phase I - IV trial delivery capabilities. Morrisville, NC, USA & London, UK - [January 05, 2026] - WEP Clinical (WEP), a full-service contract research organization (CRO), today announced the acquisition of Siron Clinical (Siron), a Netherlands-based European CRO specializing in flexible, high-quality clinical operations for biotech companies. The acquisition expands WEP's global footprint and strengthens its ability to deliver end-to-end Phase I - IV clinical trial solutions across complex, rare, and specialized therapeutic areas. Founded in 2000, Siron is headquartered in the Netherlands, with additional offices in Belgium and Germany, and clinical research professionals based across Europe and the Middle East. The company specializes in clinical operations, including project management, clinical monitoring, quality assurance, and regulatory submissions. Siron has supported more than 120 studies and is recognized for its strong track record in orphan diseases, pediatric research, and medical device trials. "This acquisition represents a significant milestone in the evolution of our CRO services. By combining WEP's global infrastructure with Siron Clinical's deep operational expertise in complex and niche indications, we can offer sponsors seamless support from early-phase development through post-approval research. Our shared culture, values, and commitment to execution excellence make this an ideal strategic fit, and we look forward to accelerating innovation and impact together." "Joining WEP gives our clients access to expanded services and global reach, while preserving the flexible, hands-on approach they value. We share WEP's commitment to quality, transparency, and patient-focused delivery, and together we will provide a more robust and scalable solution for biotech sponsors worldwide." Siron will be integrated into WEP's Clinical Trials division, enhancing WEP's existing capabilities across trial design, regulatory strategy, start-up, patient recruitment, study execution, and close-out. Clients will benefit from a larger pool of experienced CRAs, project managers, and operational leaders, alongside WEP's broader treatment access and commercialization offerings. WEP Clinical is a global Clinical Research Organization with expertise in designing, managing, and executing clinical trials across multiple therapeutic areas. With a strong focus on proactive project management, scientific integrity, regulatory compliance, and patient-centric execution, WEP supports pharmaceutical and biotech companies in bringing life-changing therapies to market efficiently and safely. Siron Clinical is a European CRO providing flexible and scalable clinical operations expertise for biotech organizations. With more than two decades of experience executing complex clinical trials, Siron delivers localized insight, hands-on support, and adaptive solutions across the clinical development journey.

WEP Clinical
Dec 1st, 2023
WEP CLINICAL HAS PARTNERED WITH PLUSULTRA PHARMA TO SUPPLY HYFTOR(R) TO PATIENTS IN EU/EEA COUNTRIES (WITH THE EXCEPTION OF GERMANY)

WEP Clinical has partnered with Plusultra pharma to supply HYFTOR(R) to patients in EU/EEA countries (with the exception of Germany).

TAIMED Biologics
Feb 3rd, 2023
TaiMed

WEP Clinical LTD (WEP), a specialist services company that works with pharmaceutical companies to help patients and physicians gain access to medicines when no other treatment options are available, has partnered with TaiMed Biologics to launch a Named Patient Program (NPP) for TROGARZO®, an IV treatment administered every two weeks for patients with muti-drug resistant HIV disease.

Yahoo Finance
Dec 21st, 2022
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a distribution agreement with WEP Clinical Ltd. (“WEP”) in connection with an early access program for DANYELZA (naxitamab-gqgk) 40mg/10mL Injection in Europe.